RHHBY Stock Recent News

Swiss drugmaker Roche said it plans to invest $50 billion in the U.S., the latest in a string of large companies boosting their presence in the country since President Donald Trump came into office.

Swiss pharmaceutical giant Roche on Tuesday said that it would invest $50 billion in the United States.

The pharma giant said the investment would create more than 12,000 new jobs, as it joins rival Novartis in expanding its footprint in the country amid President Trump's tariff threats.

Roche on Tuesday said it will invest $50 billion in the United States over the next five years, in one of the biggest inward investment moves by companies dealing with President Donald Trump's tariffs policy.

Basel, 22 April 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will invest USD 50 billion into the United States of America in the next five years. These investments further strengthen Roche's already significant US footprint with 13 manufacturing and 15 R&D sites across the Pharmaceutical and Diagnostics Divisions, and are expected to create more than 12,000 new jobs, including nearly 6,500 construction jobs,  as well as 1,000 jobs at new and expanded facilities.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #biotech--Oak Hill Bio has entered into an exclusive license agreement with Roche to obtain global rights for rugonersen for Angelman syndrome.

President Donald Trump said tariffs on pharmaceuticals will be coming in the “not too distant future” and fit in the category of tariffs imposed on cars, steel, and aluminum. Trump spoke with reporters Monday in the Oval Office.

The European Commission approves RHHBY's Columvi combo to treat adult patients with diffuse large B-cell lymphoma after initial therapy.

Basel, 14 April 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has approved Columvi® (glofitamab) in combination with gemcitabine and oxaliplatin (GemOx) for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) not otherwise specified who are ineligible for autologous stem cell transplant (ASCT). With this approval, this Columvi combination is the first bispecific antibody regimen available for people with DLBCL in Europe whose cancer has returned or for those who did not respond to initial treatment. In July 2023, Columvi received a conditional marketing authorisation to treat people with R/R DLBCL after two or more lines of systemic therapy. In addition to today's approval, a condition to convert the existing marketing authorisation to a regular approval has been fulfilled.

The Trump administration's proposed tariffs on pharmaceuticals have caused significant stock declines, but their implementation remains uncertain and may be aimed at achieving specific goals. Roche's strong U.S. presence and diversified product portfolio may mitigate the impact of potential tariffs, making it a resilient investment. Roche's promising pipeline, particularly in obesity drugs, and its solid financial performance suggest long-term growth potential despite recent stock volatility.